Trevena Inc. (NASDAQ:TRVN) SVP Yacoub Habib purchased 5,000 shares of the company’s stock in a transaction on Monday, November 7th. The stock was acquired at an average price of $4.12 per share, for a total transaction of $20,600.00. Following the completion of the transaction, the senior vice president now owns 5,000 shares of the company’s stock, valued at approximately $20,600. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Trevena Inc. (NASDAQ:TRVN) opened at 6.09 on Monday. The firm’s 50-day moving average price is $5.80 and its 200 day moving average price is $6.65. The firm’s market cap is $318.71 million. Trevena Inc. has a 12-month low of $3.76 and a 12-month high of $13.02.

Trevena (NASDAQ:TRVN) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.17. Trevena had a negative return on equity of 66.50% and a negative net margin of 841.00%. On average, equities analysts expect that Trevena Inc. will post ($1.91) earnings per share for the current fiscal year.

Several equities research analysts have commented on the stock. Cowen and Company reiterated a “buy” rating and issued a $13.00 price target on shares of Trevena in a research report on Friday, August 5th. FBR & Co reiterated a “buy” rating and issued a $13.00 price target on shares of Trevena in a research report on Thursday, August 4th. Wedbush reiterated an “outperform” rating and issued a $16.00 price target on shares of Trevena in a research report on Thursday, November 3rd. Brean Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Trevena in a research report on Friday, August 5th. Finally, Zacks Investment Research upgraded shares of Trevena from a “sell” rating to a “hold” rating in a research report on Wednesday, July 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $14.30.

Hedge funds have recently made changes to their positions in the company. BlackRock Investment Management LLC boosted its stake in shares of Trevena by 50.8% in the second quarter. BlackRock Investment Management LLC now owns 172,617 shares of the biopharmaceutical company’s stock valued at $1,087,000 after buying an additional 58,157 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Trevena by 12.5% in the second quarter. Vanguard Group Inc. now owns 1,381,542 shares of the biopharmaceutical company’s stock valued at $8,703,000 after buying an additional 153,378 shares during the last quarter. AWM Investment Company Inc. acquired a new stake in shares of Trevena during the second quarter valued at approximately $907,000. Nationwide Fund Advisors boosted its stake in shares of Trevena by 13.3% in the second quarter. Nationwide Fund Advisors now owns 69,297 shares of the biopharmaceutical company’s stock valued at $437,000 after buying an additional 8,142 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Trevena by 512.5% in the second quarter. JPMorgan Chase & Co. now owns 228,439 shares of the biopharmaceutical company’s stock valued at $1,439,000 after buying an additional 191,140 shares in the last quarter. Institutional investors own 75.52% of the company’s stock.

About Trevena

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Stock Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related stocks with our FREE daily email newsletter.